Alpine Immune Sciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Alpine Immune Sciences generated cash of -$79,012,000, which is less than the previous year. Cash used in financing activities reached the amount of $165,122,000 last year. Net change in cash is therefore $30,559,000.
Cash Flow
| 2014 | -14.44M | -4.1K | 41.16M |
|---|---|---|---|
| 2015 | -19.20M | -62.44M | 78.83M |
| 2016 | -26.25M | 25.30M | 166K |
| 2017 | -16.57M | -29.80M | 42.68M |
| 2018 | -28.41M | 32.11M | -991K |
| 2019 | -35.34M | 16.76M | 24.25M |
| 2020 | 30.08M | -72.81M | 61.38M |
| 2021 | -15.24M | -52.48M | 100.76M |
| 2022 | -43.75M | -113.34M | 102.68M |
| 2023 | -79.01M | -55.55M | 165.12M |
ALPN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.63M | 68.16M | 35.21M | 16.50M | 10.84M | 8.13M | 11.81M | 24.99M | 27.81M | 1.09M |
Operating activities | ||||||||||
Net income | -32.18M | -57.76M | -50.33M | -27.94M | -41.85M | -36.48M | -7.78M | -31.46M | -22.81M | -15.03M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 576K | 597K | 620K | 578K | 468K | 388K | 241K | 143K | 66K | 86.44K |
Stock-based compensation expense | 10.63M | 9.64M | 6.24M | 4.14M | 3.04M | 0 | 838K | 3.26M | 1.34M | 69.62K |
| Deferred income tax benefit | 10.63M | 9.64M | 6.24M | 4.14M | 3.04M | 0 | 838K | 3.26M | 1.34M | 69.62K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 225K | 24.60M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 6.51M | 5.55M | 5.97M | -491K | 816K | 1.52M | 66K | 927K | 65K | 258.25K |
Cash generated by operating activities | -79.01M | -43.75M | -15.24M | 30.08M | -35.34M | -28.41M | -16.57M | -26.25M | -19.20M | -14.44M |
Investing activities | ||||||||||
Purchases Of Investments | -351.34M | -266.98M | -133.51M | -101.32M | -59.38M | -72.86M | -88.30M | -75.32M | -76.26M | 0 |
Investments In Property Plant And Equipment | -487K | -412K | -118K | -802K | -821K | -495K | -586K | -106K | -188K | -4.1K |
Acquisitions Net | 0 | 112.93M | 52.36M | 72.01M | -17.58M | 0 | 31.13M | 0 | 0 | 0 |
Cash generated by investing activities | -55.55M | -113.34M | -52.48M | -72.81M | 16.76M | 32.11M | -29.80M | 25.30M | -62.44M | -4.1K |
Financing activities | ||||||||||
Common Stock Issued | 168.54M | 106.71M | 102.66M | 56.25M | 23.59M | 9K | 37.66M | 20K | 78.77M | 11.86M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -2.4M | -5M | 0 | -1M | 0 | 0 | 0 | -3.13M |
Cash used in financing activities | 165.12M | 102.68M | 100.76M | 61.38M | 24.25M | -991K | 42.68M | 166K | 78.83M | 41.16M |
Net Change In Cash | 30.55M | -54.53M | 32.94M | 18.70M | 5.66M | 2.71M | -3.68M | -788K | -2.82M | 26.71M |
Cash at end of period | 44.18M | 13.63M | 68.16M | 35.21M | 16.50M | 10.84M | 8.13M | 24.20M | 24.99M | 27.81M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |